TAT

tyrosine aminotransferase

Basic information

Region (hg38): 16:71565660-71577092

Links

ENSG00000198650NCBI:6898OMIM:613018HGNC:11573Uniprot:P17735AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • tyrosinemia type II (Definitive), mode of inheritance: AR
  • tyrosinemia type II (Definitive), mode of inheritance: AR
  • tyrosinemia type II (Strong), mode of inheritance: AR
  • tyrosinemia type II (Strong), mode of inheritance: AR
  • tyrosinemia type II (Supportive), mode of inheritance: AR
  • tyrosinemia type II (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Tyrosinemia, type IIARBiochemicalDietary measures (controlled intake of phenylalanine and tyrosine) can be effective, including as relates to neurocognitive outcomeBiochemical; Dermatologic; Neurologic; Ophthalmologic18901242; 33934; 6446465; 1356171; 1357662; 8912606; 12227462; 9544843; 16574453; 16917729; 18945316; 21145993; 21636300

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the TAT gene.

  • Tyrosinemia type II (12 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the TAT gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
153
clinvar
3
clinvar
156
missense
6
clinvar
47
clinvar
2
clinvar
2
clinvar
57
nonsense
5
clinvar
7
clinvar
12
start loss
1
clinvar
1
frameshift
6
clinvar
15
clinvar
21
inframe indel
0
splice donor/acceptor (+/-2bp)
1
clinvar
16
clinvar
1
clinvar
18
splice region
1
5
31
37
non coding
26
clinvar
86
clinvar
8
clinvar
120
Total 12 45 74 241 13

Highest pathogenic variant AF is 0.00000657

Variants in TAT

This is a list of pathogenic ClinVar variants found in the TAT region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-71566867-TA-T Hypertyrosinemia Uncertain significance (Jun 14, 2016)320385
16-71566868-A-T Tyrosinemia type II Benign (Jan 13, 2018)320386
16-71567078-C-T Tyrosinemia type II Uncertain significance (Jan 12, 2018)320387
16-71567088-C-G Tyrosinemia type II Likely benign (Jan 12, 2018)320388
16-71567089-T-C Tyrosinemia type II Uncertain significance (Jan 12, 2018)320389
16-71567153-A-G Tyrosinemia type II Uncertain significance (Jan 13, 2018)887362
16-71567161-T-C Tyrosinemia type II Uncertain significance (Jan 13, 2018)320390
16-71567281-C-T Tyrosinemia type II Likely benign (Jan 12, 2018)887363
16-71567292-C-T Tyrosinemia type II Uncertain significance (Jan 13, 2018)320391
16-71567331-C-G Tyrosinemia type II Likely benign (Jan 12, 2018)320392
16-71567370-C-T Tyrosinemia type II Uncertain significance (Jan 13, 2018)320393
16-71567402-C-T Tyrosinemia type II Uncertain significance (Jan 13, 2018)887549
16-71567431-A-C Tyrosinemia type II Uncertain significance (Jan 13, 2018)887550
16-71567462-A-G Tyrosinemia type II Likely benign (Jan 12, 2018)320394
16-71567484-C-G Tyrosinemia type II Uncertain significance (Jan 13, 2018)887551
16-71567563-C-T Tyrosinemia type II Uncertain significance (Jan 12, 2018)320395
16-71567665-A-T Tyrosinemia type II Uncertain significance (Jan 13, 2018)887552
16-71567735-C-T Tyrosinemia type II Uncertain significance (Apr 27, 2017)887553
16-71567741-C-A Tyrosinemia type II Uncertain significance (Apr 27, 2017)887554
16-71567747-T-TAG Hypertyrosinemia Likely benign (Jun 14, 2016)320396
16-71567791-TTTC-T Hypertyrosinemia Uncertain significance (Jun 14, 2016)320397
16-71567891-C-G Tyrosinemia type II Uncertain significance (Jan 13, 2018)884401
16-71567892-G-C Tyrosinemia type II Uncertain significance (Jan 12, 2018)320398
16-71567893-A-T Tyrosinemia type II Uncertain significance (Jan 13, 2018)320399
16-71567925-C-T Tyrosinemia type II Uncertain significance (Jan 12, 2018)320400

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
TATprotein_codingprotein_codingENST00000355962 1111471
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.006900.9921257320161257480.0000636
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.7602202540.8660.00001472969
Missense in Polyphen5783.6540.68138996
Synonymous0.3848993.70.9500.00000527884
Loss of Function2.97823.50.3400.00000139275

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001200.000120
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.000.00
European (Non-Finnish)0.00008800.0000879
Middle Eastern0.00005440.0000544
South Asian0.00006530.0000653
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transaminase involved in tyrosine breakdown. Converts tyrosine to p-hydroxyphenylpyruvate. Can catalyze the reverse reaction, using glutamic acid, with 2-oxoglutarate as cosubstrate (in vitro). Has much lower affinity and transaminase activity towards phenylalanine. {ECO:0000269|PubMed:16640556, ECO:0000269|PubMed:7999802}.;
Disease
DISEASE: Tyrosinemia 2 (TYRSN2) [MIM:276600]: An inborn error of metabolism characterized by elevations of tyrosine in the blood and urine, and oculocutaneous manifestations. Typical features include palmoplantar keratosis, painful corneal ulcers, and mental retardation. {ECO:0000269|PubMed:1357662}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Phenylalanine metabolism - Homo sapiens (human);Phenylalanine, tyrosine and tryptophan biosynthesis - Homo sapiens (human);Cysteine and methionine metabolism - Homo sapiens (human);Tyrosine metabolism - Homo sapiens (human);Tyrosinemia, transient, of the newborn;Dopamine beta-hydroxylase deficiency;Disulfiram Action Pathway;Phenylalanine and Tyrosine Metabolism;Tyrosine Metabolism;Alkaptonuria;Monoamine oxidase-a deficiency (MAO-A);Hawkinsinuria;Tyrosinemia Type I;Phenylketonuria;Tyrosinemia Type 3 (TYRO3);Tyrosinemia Type 2 (or Richner-Hanhart syndrome);Methionine De Novo and Salvage Pathway;Amino Acid metabolism;Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism;Metabolism of amino acids and derivatives;Phenylalanine and tyrosine catabolism;Metabolism;Phenylalanine degradation;tyrosine degradation;4-hydroxybenzoate biosynthesis;Methionine and cysteine metabolism;Tyrosine metabolism;FOXA2 and FOXA3 transcription factor networks (Consensus)

Recessive Scores

pRec
0.709

Intolerance Scores

loftool
0.244
rvis_EVS
-0.56
rvis_percentile_EVS
19.54

Haploinsufficiency Scores

pHI
0.376
hipred
Y
hipred_score
0.683
ghis
0.440

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.999

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Tat
Phenotype

Gene ontology

Biological process
2-oxoglutarate metabolic process;glutamate metabolic process;L-phenylalanine catabolic process;tyrosine catabolic process;response to oxidative stress;biosynthetic process;response to mercury ion;response to glucocorticoid
Cellular component
cellular_component;mitochondrion;cytosol
Molecular function
L-tyrosine:2-oxoglutarate aminotransferase activity;protein binding;amino acid binding;pyridoxal phosphate binding